[
  {
    "ts": null,
    "headline": "The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.",
    "summary": "Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.",
    "url": "https://finnhub.io/api/news?id=06b89f264196d37527ecb26d7446e4fc1bba0450f69d3c1d210caea8c6eab5d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749240397,
      "headline": "The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.",
      "id": 135082831,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.",
      "url": "https://finnhub.io/api/news?id=06b89f264196d37527ecb26d7446e4fc1bba0450f69d3c1d210caea8c6eab5d7"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
    "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=29061a09477fc3df67f22c43c87f53b38676c14992e08262ba2fec73dd9a2564",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749227700,
      "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
      "id": 135091644,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=29061a09477fc3df67f22c43c87f53b38676c14992e08262ba2fec73dd9a2564"
    }
  },
  {
    "ts": null,
    "headline": "Harbor Large Cap Value Fund Q1 2025 Commentary",
    "summary": "Portfolio ManagersHoward Gleicher andÂ Gregory D. PadillaInvestment PhilosophyThe Fund invests primarily in equity securities, principally common and...",
    "url": "https://finnhub.io/api/news?id=b04f7a8e57d11773a0384432234a023389a5895b49e039ce1fe86136eaf02254",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749211320,
      "headline": "Harbor Large Cap Value Fund Q1 2025 Commentary",
      "id": 135080057,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/172153253/image_172153253.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Portfolio ManagersHoward Gleicher andÂ Gregory D. PadillaInvestment PhilosophyThe Fund invests primarily in equity securities, principally common and...",
      "url": "https://finnhub.io/api/news?id=b04f7a8e57d11773a0384432234a023389a5895b49e039ce1fe86136eaf02254"
    }
  },
  {
    "ts": null,
    "headline": "2 Dividend Growth Stocks to Buy and Hold Forever",
    "summary": "Novartis and Amgen also boast impeccable dividend track records, which should please investors.  Let's consider two examples in the healthcare sector: Amgen (NASDAQ: AMGN) and Novartis (NYSE: NVS).  Amgen's organic revenue hasn't always grown as fast as Wall Street would have wanted over the past few years.",
    "url": "https://finnhub.io/api/news?id=5f1771f4dda4a14377df17189d1034a89e8ac7f64f657a94a0b9c9167553de26",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749206700,
      "headline": "2 Dividend Growth Stocks to Buy and Hold Forever",
      "id": 135074102,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Novartis and Amgen also boast impeccable dividend track records, which should please investors.  Let's consider two examples in the healthcare sector: Amgen (NASDAQ: AMGN) and Novartis (NYSE: NVS).  Amgen's organic revenue hasn't always grown as fast as Wall Street would have wanted over the past few years.",
      "url": "https://finnhub.io/api/news?id=5f1771f4dda4a14377df17189d1034a89e8ac7f64f657a94a0b9c9167553de26"
    }
  },
  {
    "ts": null,
    "headline": "Amgen's Strategic Path - Navigating Patent Expiries With Promising New Therapies",
    "summary": "Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs to offset losses. Learn why AMGN stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=061341b4ee59b9866db9f6d4b58407311b12bf3760ed843ad32dfc6d4c9dbf0c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749177074,
      "headline": "Amgen's Strategic Path - Navigating Patent Expiries With Promising New Therapies",
      "id": 135069407,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2214346556/image_2214346556.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs to offset losses. Learn why AMGN stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=061341b4ee59b9866db9f6d4b58407311b12bf3760ed843ad32dfc6d4c9dbf0c"
    }
  }
]